Muscle Microdialysis to Investigate Inflammatory Biomarkers in Facioscapulohumeral Muscular Dystrophy

Giorgio Tasca, Mauro Monforte, Maddalena Corbi, Giuseppe Granata, Donatella Lucchetti, Alessandro Sgambato, Enzo Ricci

Research output: Contribution to journalArticle

Abstract

Recent progresses in the understanding of facioscapulohumeral muscular dystrophy (FSHD) genetics opened the way to the development of targeted therapies. However, knowledge about pathophysiology of muscle damage is still limited and there is increasing need to identify biomarkers of disease activity in the perspective of clinical trial readiness. We analyzed inflammatory mediators in the interstitial fluid of muscles with different MRI signal in FSHD patients, comparing muscles displaying early lesions on short-tau inversion recovery (STIR) sequences with normal ones. Patients with one T1-weighted normal and STIR hyperintense (STIR+) and contralateral T1-weighted and STIR normal (STIR-) lower limb muscle were asked to enter the study. Twelve consecutive patients, five controls, and one non-penetrant gene carrier underwent prolonged muscle microdialysis with high cut-off membranes. Microdialysates were analyzed using xMAP technology with a wide panel for cytokines, chemokines, and growth factors. A small number of inflammatory mediators were dysregulated in STIR+ versus STIR- and control muscles: CXCL13, upregulated in STIR+ muscles compared with controls (p OpenSPiltSPi 0.01); CXCL5, downregulated in STIR+ compared with STIR- muscles (p OpenSPiltSPi 0.05); and G-CSF, downregulated in STIR+ muscles compared with controls (p OpenSPiltSPi 0.05). CXCL13 was also upregulated in the STIR+ muscles compared with the contralateral STIR- muscles of the same patient (p OpenSPiltSPi 0.01). These results support the evidence of a selective inflammatory process taking place in STIR+ FSHD muscles. The application of microdialysis could provide insights on novel mechanisms involved in muscle damage in FSHD and in other myopathies. Further studies are needed to validate these investigated molecules as tissue and circulating biomarkers.

Original languageEnglish
Pages (from-to)2959-2966
Number of pages8
JournalMolecular Neurobiology
Volume55
Issue number4
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Facioscapulohumeral Muscular Dystrophy
Microdialysis
Biomarkers
Muscles
Down-Regulation
Sequence Inversion
Extracellular Fluid
Granulocyte Colony-Stimulating Factor
Muscular Diseases

Keywords

  • Biomarkers
  • CXCL13
  • Cytokines
  • Facioscapulohumeral muscular dystrophy
  • FSHD
  • Microdialysis

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

Muscle Microdialysis to Investigate Inflammatory Biomarkers in Facioscapulohumeral Muscular Dystrophy. / Tasca, Giorgio; Monforte, Mauro; Corbi, Maddalena; Granata, Giuseppe; Lucchetti, Donatella; Sgambato, Alessandro; Ricci, Enzo.

In: Molecular Neurobiology, Vol. 55, No. 4, 01.04.2018, p. 2959-2966.

Research output: Contribution to journalArticle

Tasca, Giorgio ; Monforte, Mauro ; Corbi, Maddalena ; Granata, Giuseppe ; Lucchetti, Donatella ; Sgambato, Alessandro ; Ricci, Enzo. / Muscle Microdialysis to Investigate Inflammatory Biomarkers in Facioscapulohumeral Muscular Dystrophy. In: Molecular Neurobiology. 2018 ; Vol. 55, No. 4. pp. 2959-2966.
@article{9ab3712c49e44fde92da0f6e28bded01,
title = "Muscle Microdialysis to Investigate Inflammatory Biomarkers in Facioscapulohumeral Muscular Dystrophy",
abstract = "Recent progresses in the understanding of facioscapulohumeral muscular dystrophy (FSHD) genetics opened the way to the development of targeted therapies. However, knowledge about pathophysiology of muscle damage is still limited and there is increasing need to identify biomarkers of disease activity in the perspective of clinical trial readiness. We analyzed inflammatory mediators in the interstitial fluid of muscles with different MRI signal in FSHD patients, comparing muscles displaying early lesions on short-tau inversion recovery (STIR) sequences with normal ones. Patients with one T1-weighted normal and STIR hyperintense (STIR+) and contralateral T1-weighted and STIR normal (STIR-) lower limb muscle were asked to enter the study. Twelve consecutive patients, five controls, and one non-penetrant gene carrier underwent prolonged muscle microdialysis with high cut-off membranes. Microdialysates were analyzed using xMAP technology with a wide panel for cytokines, chemokines, and growth factors. A small number of inflammatory mediators were dysregulated in STIR+ versus STIR- and control muscles: CXCL13, upregulated in STIR+ muscles compared with controls (p OpenSPiltSPi 0.01); CXCL5, downregulated in STIR+ compared with STIR- muscles (p OpenSPiltSPi 0.05); and G-CSF, downregulated in STIR+ muscles compared with controls (p OpenSPiltSPi 0.05). CXCL13 was also upregulated in the STIR+ muscles compared with the contralateral STIR- muscles of the same patient (p OpenSPiltSPi 0.01). These results support the evidence of a selective inflammatory process taking place in STIR+ FSHD muscles. The application of microdialysis could provide insights on novel mechanisms involved in muscle damage in FSHD and in other myopathies. Further studies are needed to validate these investigated molecules as tissue and circulating biomarkers.",
keywords = "Biomarkers, CXCL13, Cytokines, Facioscapulohumeral muscular dystrophy, FSHD, Microdialysis",
author = "Giorgio Tasca and Mauro Monforte and Maddalena Corbi and Giuseppe Granata and Donatella Lucchetti and Alessandro Sgambato and Enzo Ricci",
year = "2018",
month = "4",
day = "1",
doi = "10.1007/s12035-017-0563-x",
language = "English",
volume = "55",
pages = "2959--2966",
journal = "Molecular Neurobiology",
issn = "0893-7648",
publisher = "Humana Press Inc.",
number = "4",

}

TY - JOUR

T1 - Muscle Microdialysis to Investigate Inflammatory Biomarkers in Facioscapulohumeral Muscular Dystrophy

AU - Tasca, Giorgio

AU - Monforte, Mauro

AU - Corbi, Maddalena

AU - Granata, Giuseppe

AU - Lucchetti, Donatella

AU - Sgambato, Alessandro

AU - Ricci, Enzo

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Recent progresses in the understanding of facioscapulohumeral muscular dystrophy (FSHD) genetics opened the way to the development of targeted therapies. However, knowledge about pathophysiology of muscle damage is still limited and there is increasing need to identify biomarkers of disease activity in the perspective of clinical trial readiness. We analyzed inflammatory mediators in the interstitial fluid of muscles with different MRI signal in FSHD patients, comparing muscles displaying early lesions on short-tau inversion recovery (STIR) sequences with normal ones. Patients with one T1-weighted normal and STIR hyperintense (STIR+) and contralateral T1-weighted and STIR normal (STIR-) lower limb muscle were asked to enter the study. Twelve consecutive patients, five controls, and one non-penetrant gene carrier underwent prolonged muscle microdialysis with high cut-off membranes. Microdialysates were analyzed using xMAP technology with a wide panel for cytokines, chemokines, and growth factors. A small number of inflammatory mediators were dysregulated in STIR+ versus STIR- and control muscles: CXCL13, upregulated in STIR+ muscles compared with controls (p OpenSPiltSPi 0.01); CXCL5, downregulated in STIR+ compared with STIR- muscles (p OpenSPiltSPi 0.05); and G-CSF, downregulated in STIR+ muscles compared with controls (p OpenSPiltSPi 0.05). CXCL13 was also upregulated in the STIR+ muscles compared with the contralateral STIR- muscles of the same patient (p OpenSPiltSPi 0.01). These results support the evidence of a selective inflammatory process taking place in STIR+ FSHD muscles. The application of microdialysis could provide insights on novel mechanisms involved in muscle damage in FSHD and in other myopathies. Further studies are needed to validate these investigated molecules as tissue and circulating biomarkers.

AB - Recent progresses in the understanding of facioscapulohumeral muscular dystrophy (FSHD) genetics opened the way to the development of targeted therapies. However, knowledge about pathophysiology of muscle damage is still limited and there is increasing need to identify biomarkers of disease activity in the perspective of clinical trial readiness. We analyzed inflammatory mediators in the interstitial fluid of muscles with different MRI signal in FSHD patients, comparing muscles displaying early lesions on short-tau inversion recovery (STIR) sequences with normal ones. Patients with one T1-weighted normal and STIR hyperintense (STIR+) and contralateral T1-weighted and STIR normal (STIR-) lower limb muscle were asked to enter the study. Twelve consecutive patients, five controls, and one non-penetrant gene carrier underwent prolonged muscle microdialysis with high cut-off membranes. Microdialysates were analyzed using xMAP technology with a wide panel for cytokines, chemokines, and growth factors. A small number of inflammatory mediators were dysregulated in STIR+ versus STIR- and control muscles: CXCL13, upregulated in STIR+ muscles compared with controls (p OpenSPiltSPi 0.01); CXCL5, downregulated in STIR+ compared with STIR- muscles (p OpenSPiltSPi 0.05); and G-CSF, downregulated in STIR+ muscles compared with controls (p OpenSPiltSPi 0.05). CXCL13 was also upregulated in the STIR+ muscles compared with the contralateral STIR- muscles of the same patient (p OpenSPiltSPi 0.01). These results support the evidence of a selective inflammatory process taking place in STIR+ FSHD muscles. The application of microdialysis could provide insights on novel mechanisms involved in muscle damage in FSHD and in other myopathies. Further studies are needed to validate these investigated molecules as tissue and circulating biomarkers.

KW - Biomarkers

KW - CXCL13

KW - Cytokines

KW - Facioscapulohumeral muscular dystrophy

KW - FSHD

KW - Microdialysis

UR - http://www.scopus.com/inward/record.url?scp=85018313854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018313854&partnerID=8YFLogxK

U2 - 10.1007/s12035-017-0563-x

DO - 10.1007/s12035-017-0563-x

M3 - Article

C2 - 28456937

AN - SCOPUS:85018313854

VL - 55

SP - 2959

EP - 2966

JO - Molecular Neurobiology

JF - Molecular Neurobiology

SN - 0893-7648

IS - 4

ER -